The company said its Q4 2023 reported sales rose 7.3% to $21.4 Billion, with EPS of $1.70 (up 39.3%) and adjusted EPS of $2.29 (up 11.7%).

1. 01

   The company said its Q4 2023 reported sales rose 7.3% to $21.4 Billion, with EPS of $1.70 (up 39.3%) and adjusted EPS of $2.29 (up 11.7%).

2. 02

   Johnson & Johnson said full-year 2023 reported sales rose 6.5% to $85.2 billion. Full-year EPS of $5.20 fell 15.3%, which it attributed to a special one-time charge in Q1, while adjusted EPS rose 11.1% to $9.92.

3. 03

   The company said full-year 2023 operational sales for Innovative Medicine, excluding the COVID-19 Vaccine, grew 7.2%. It said MedTech operational sales grew 12.4%, and that the acquisition of Abiomed contributed 4.7% of that growth.

4. 04

   Johnson & Johnson said it re-confirmed its full-year 2024 guidance, which calls for operational sales growth excluding the COVID-19 Vaccine of 5.0% to 6.0% and adjusted operational EPS of $10.55 to $10.75.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.